{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:50Z","timestamp":1772166230241,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:00:00Z","timestamp":1639872000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003511"],"award-info":[{"award-number":["82003511"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2042020kf1018"],"award-info":[{"award-number":["2042020kf1018"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver fibrosis is common in individuals with HIV\/HBV co-infection, but whether cART could reverses liver fibrosis is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a retrospective observational study. Binary logistic regression was used to assess predictors of liver fibrosis in individuals with HIV\/HBV co-infection. Comparison of FIB-4 scores before and after cART were compared using\n                      <jats:italic>X<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      test and\n                      <jats:italic>t<\/jats:italic>\n                      test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four hundred and fifty-eight individuals with HIV\/HBV co-infection were included in this study. It was found that cART (HR 0.016, 95% CI: 0.009\u20130.136; P\u2009&lt;\u20090.001) was one of protection factors to against liver fibrosis. Forty individuals who had normal levels of ALT, AST and PLT during the whole course of diseases were stratified into FIB-4\u2009&lt;\u20091.45 (n\u2009=\u200914), 1.45\u2009\u2264\u2009FIB-4\u2009\u2264\u20093.25 (n\u2009=\u200919) and FIB-4\u2009&gt;\u20093.25 (n\u2009=\u20097) groups by their FIB-4 scores before cART. In 1.45\u2009\u2264\u2009FIB-4\u2009\u2264\u20093.25 group, 57.9%(11\/19) of the individuals dropped to FIB-4\u2009&lt;\u20091.45 group by cART; in FIB-4\u2009&gt;\u20093.25 group, 85.7%(6\/79) dropped to 1.45\u2009\u2264\u2009FIB-4\u2009\u2264\u20093.25 group, while 14.3%(1\/7) dropped to FIB-4\u2009&lt;\u20091.45 group. In cART-naive group, 1\u00a0year, 2\u20135\u00a0years and 5\u201310\u00a0years post-cART groups, FIB-4 scores were 4.29\u2009\u00b1\u20090.43, 3.63\u2009\u00b1\u20090.38, 2.90\u2009\u00b1\u20090.36 and 2.52\u2009\u00b1\u20090.38, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.034); and the incidence of liver fibrosis were 7.38%(104\/141), 63.6%(98\/154), 60.8%(62\/102) and 47.5%(29\/61), respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>cART was associated with decreased FIB-4 scores and the benefit of cART in reversing liver fibrosis can sustain for a decade in patients with HIV\/HBV co-infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-021-00419-y","type":"journal-article","created":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:02:38Z","timestamp":1639872158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Combination antiretroviral therapy is associated with reduction in liver fibrosis scores in patients with HIV and HBV co-infection"],"prefix":"10.1186","volume":"18","author":[{"given":"Rongrong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xien","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengning","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shicheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,19]]},"reference":[{"key":"419_CR1","doi-asserted-by":"crossref","unstructured":"Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24(10):1537\u201348.","DOI":"10.1097\/QAD.0b013e32833a0918"},{"key":"419_CR2","first-page":"2371","volume":"125","author":"YJ Li","year":"2012","unstructured":"Li YJ, Wang HL, Li TS. Hepatitis B virus\/human immunodeficiency virus coinfection: interaction among human immunodeficiency virus infection, chronic hepatitis B virus infection, and host immunity. Chin Med J (Engl). 2012;125:2371\u20137.","journal-title":"Chin Med J (Engl)"},{"key":"419_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","volume":"11","author":"JY Chen","year":"2014","unstructured":"Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:362\u201371.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"419_CR4","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1002\/hep.22883","volume":"49","author":"CL Thio","year":"2009","unstructured":"Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49:S138\u201345.","journal-title":"Hepatology"},{"key":"419_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/infdis\/jir885","volume":"205","author":"JC Price","year":"2012","unstructured":"Price JC, Seaberg EC, Badri S, Witt MD, D\u2019Acunto K, Thio CL. HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis. 2012;205:1005\u201313.","journal-title":"J Infect Dis"},{"key":"419_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/jvh.13058","volume":"26","author":"Y Kong","year":"2019","unstructured":"Kong Y, Sun Y, Zhou J, Wu X, Chen Y, Piao H, et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. J Viral Hepat. 2019;26:576\u201385.","journal-title":"J Viral Hepat"},{"key":"419_CR7","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/hep.29009","volume":"65","author":"Y Sun","year":"2017","unstructured":"Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;65:1438\u201350.","journal-title":"Hepatology"},{"issue":"1","key":"419_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32\u20136.","journal-title":"Hepatology"},{"issue":"4 Suppl 3","key":"419_CR9","doi-asserted-by":"publisher","first-page":"19643","DOI":"10.7448\/IAS.17.4.19643","volume":"17","author":"EO Gonzalez","year":"2014","unstructured":"Gonzalez EO, Boix V, Deltoro MG, Aldeguer JL, Portilla J, Montero M, et al. The effects of Maraviroc on liver fibrosis in HIV\/HCV co-infected patients. J Int AIDS Soc. 2014;17(4 Suppl 3):19643.","journal-title":"J Int AIDS Soc"},{"key":"419_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2334-14-79","volume":"14","author":"G Marchetti","year":"2014","unstructured":"Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, et al. Immune activation and microbial translocation in liver disease progression in HIV\/hepatitis co-infected patients: results from the Icona Foundation Study. BMC Infect Dis. 2014;14:79.","journal-title":"BMC Infect Dis"},{"key":"419_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/QAD.0b013e3283410ccb","volume":"25","author":"DM Iser","year":"2011","unstructured":"Iser DM, Avihingsanon A, Wisedopas N, Thompson AJ, Boyd A, Matthews GV, et al. Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS. 2011;25:197\u2013205.","journal-title":"AIDS"},{"issue":"11","key":"419_CR12","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1097\/QAD.0000000000001018","volume":"30","author":"L Ryom","year":"2016","unstructured":"Ryom L, Lundgren JD, De Wit S, Kovari H, Reiss P, Law M, et al. Use of antiretroviral therapy and risk of endstage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS. 2016;30(11):1731\u201343.","journal-title":"AIDS"},{"key":"419_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1365-2893.2012.01596.x","volume":"19","author":"T Su\u00e1rez-Zarracina","year":"2012","unstructured":"Su\u00e1rez-Zarracina T, Valle-Garay E, Collazos J, Montes AH, C\u00e1rcaba V, Carton JA, et al. Didanosine (ddI) associates with increased liver fibrosis in adult HIV\u2013HCV coinfected patients. J Viral Hepat. 2012;19:685\u201393.","journal-title":"J Viral Hepat"},{"key":"419_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/cid\/ciq199","volume":"52","author":"JT Blackard","year":"2011","unstructured":"Blackard JT, Welge JA, Taylor LE, Mayer KH, Klein RS, Celentano DD, et al. HIV mono-infection is associated with FIB-4\u2014a noninvasive index of liver fibrosis- in women. Clin Infect Dis. 2011;52:674\u201380.","journal-title":"Clin Infect Dis"},{"key":"419_CR15","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/cid\/ciu097","volume":"58","author":"JK Lim","year":"2014","unstructured":"Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, et al. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis. 2014;58:1449\u201358.","journal-title":"Clin Infect Dis"},{"key":"419_CR16","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1111\/j.1365-2893.2011.01529.x","volume":"19","author":"JE Forrester","year":"2012","unstructured":"Forrester JE, Rhee MS, McGovern BH, Sterling RK, Knox TA, Terrin N. The association of HIV viral load with indirect markers of liver injury. J Viral Hepat. 2012;19:e202\u201311.","journal-title":"J Viral Hepat"},{"key":"419_CR17","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4254\/wjh.v5.i10.584","volume":"5","author":"M Tahiri","year":"2013","unstructured":"Tahiri M, Sodqi M, Lahdami FEZ, Marih L, Lamdini H, Hliwa W, et al. Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco. World J Hepatol. 2013;5:584\u20138.","journal-title":"World J Hepatol"},{"key":"419_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1053\/j.gastro.2008.03.022","volume":"135","author":"A Balagopal","year":"2008","unstructured":"Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 2008;135:226\u201333.","journal-title":"Gastroenterology"},{"key":"419_CR19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/infdis\/jit225","volume":"208","author":"AL French","year":"2013","unstructured":"French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, et al. Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J Infect Dis. 2013;208:679\u201389.","journal-title":"J Infect Dis"},{"key":"419_CR20","unstructured":"French AL, Peters M, Evans C, Young M, Desai S, Kuniholm M, et al. Macrophage activation and hepatitis C (HCV) disease progression in HIV-infected women participating in the women\u2019s interagency HIV study (WIHS). In: Conference on Retroviruses and Opportunistic Iiinfections. Seattle, Washington; 2015."},{"key":"419_CR21","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/hep.27303","volume":"61","author":"MH Kuniholm","year":"2015","unstructured":"Kuniholm MH, Hanna DB, Landay AL, Kaplan RC, Ley K. Soluble CD163 is associated with noninvasive measures of liver fibrosis in hepatitis C virus- and hepatitis C virus\/human immunodeficiency virus-infected women. Hepatology. 2015;61:734\u20135.","journal-title":"Hepatology"},{"key":"419_CR22","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1097\/QAD.0000000000001119","volume":"30","author":"KW Kooij","year":"2016","unstructured":"Kooij KW, Wit FW, van Zoest RA, Schouten J, Kootstra NA, van Vugt M, et al. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. AIDS. 2016;30:1771\u201380.","journal-title":"AIDS"},{"issue":"9","key":"419_CR23","doi-asserted-by":"publisher","first-page":"e0138838","DOI":"10.1371\/journal.pone.0138838","volume":"10","author":"P Schmid","year":"2015","unstructured":"Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, M\u00fcllhaupt B, et al. Progression of liver fibrosis in HIV\/HCV co-infection: a comparison between non-invasive assessment methods and liver biopsy. PLoS ONE. 2015;10(9):e0138838.","journal-title":"PLoS ONE"},{"issue":"7","key":"419_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3851\/IMP1649","volume":"15","author":"A Boyd","year":"2010","unstructured":"Boyd A, Lasnier E, Molina JM, Lascoux-Combe C, Bonnard P, Miailhes P, et al. Liver fibrosis changes in individuals with HIV\/HBV co-infection: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther. 2010;15(7):963\u201374.","journal-title":"Antivir Ther"},{"issue":"10","key":"419_CR25","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/cid\/cix122","volume":"64","author":"MJ Vinikoor","year":"2017","unstructured":"Vinikoor MJ, Sinkala E, Chilengi R, Mulenga LB, Chi BH, Zyambo Z, et al. Impact of antiretroviral therapy on liver fibrosis among human immunodeficiency virus-infected adults with and without HBV coinfection in Zambia. Clin Infect Dis. 2017;64(10):1343\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"419_CR26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/QAD.0b013e32835cb9c8","volume":"27","author":"C Hawkins","year":"2013","unstructured":"Hawkins C, Christian B, Ye J, Nagu T, Aris E, Chalamilla G, et al. Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV infected patients in Tanzania. AIDS. 2013;27(6):919\u201327.","journal-title":"AIDS"},{"key":"419_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ijid.2016.08.028","volume":"51","author":"G Wandeler","year":"2016","unstructured":"Wandeler G, Mulenga L, Vinikoor MJ, Kovari H, Battegay M, Calmy A, et al. Liver fibrosis in treatment-naive HIV-infected and HIV\/HBV co-infected patients: Zambia and Switzerland compared. Int J Infect Dis. 2016;51:97\u2013102.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"419_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2010.03.007","volume":"53","author":"P Cal\u00e8s","year":"2010","unstructured":"Cal\u00e8s P, Halfon P, Batisse D, Carrat F, Perr\u00e9 P, Penaranda G, et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV\/HCV co-infection. J Hepatol. 2010;53(2):238\u201344.","journal-title":"J Hepatol"},{"issue":"1","key":"419_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/hep.27382","volume":"61","author":"G Xiao","year":"2015","unstructured":"Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292\u2013302.","journal-title":"Hepatology"},{"issue":"4","key":"419_CR30","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4103\/0366-6999.151078","volume":"128","author":"HW Fan","year":"2015","unstructured":"Fan HW, Guo FP, Li YJ, Li N, Li TS. Prevalence of thrombocytopenia among Chinese adult antiretroviral-naive HIV-positive patients. Chin Med J (Engl). 2015;128(4):459\u201364.","journal-title":"Chin Med J (Engl)"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00419-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-021-00419-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00419-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T12:05:27Z","timestamp":1639915527000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-021-00419-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1186\/s12981-021-00419-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-795225\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"9 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Zhongnan Hospital of Wuhan University. Written informed consent to participate this study can be obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication can be obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}